Determinants of serum antipyrine half-lives in patients with liver disease.

Gut ·Vol. 14 ·No. 7 ·1973-07-00 ·Pages 569-73

Branch RA, Herbert CM, Read AE

Abstract

Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T(1/2)) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T(1/2) was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.

MeSH Terms

Adult Alkaline Phosphatase/blood Antipyrine/blood,metabolism Aspartate Aminotransferases/blood Bilirubin/blood Half-Life Hepatitis/blood Humans Hypoproteinemia/blood Hypoprothrombinemias/blood Liver Cirrhosis/blood Liver Diseases/blood Liver Function Tests Microsomes, Liver/enzymology Middle Aged Phenobarbital Prednisone Prothrombin/analysis Serum Albumin/analysis

Chemicals

Serum Albumin Prothrombin Aspartate Aminotransferases Alkaline Phosphatase Bilirubin Antipyrine Prednisone Phenobarbital

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Branch R A

Herbert C M

Read A E

References (14)

14 references, click to expand

Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.
Lancet. 1968 Jun 15;1(7555):1275-9 PMID: 4172137
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
J Clin Invest. 1969 Dec;48(12):2202-9 PMID: 5389794
Pharmacodynamics of carbenicillin in hepatic and renal failure.
Ann Intern Med. 1970 Aug;73(2):173-8 PMID: 5454254
Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.
Circulation. 1971 Feb;43(2):205-11 PMID: 5540706
The effect of hepatic blood flow on the hepatic removal rate of oxyphenbutazone in the dog.
J Pharmacol Exp Ther. 1971 Apr;177(1):246-55 PMID: 5566766
Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.
Gut. 1972 Jan;13(1):47-53 PMID: 5060669
Influence of nitrazepam on oral anticoagulation with phenprocoumon.
Clin Pharmacol Ther. 1972 May-Jun;13(3):361-5 PMID: 4554660
Metabolism of amylobarbitone in patients with chronic liver disease.
Br J Pharmacol. 1972 Mar;44(3):549-60 PMID: 5040665
Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease.
Am J Med Sci. 1954 Jul;228(1):36-9 PMID: 13171379
Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs.
J Pharmacol Exp Ther. 1960 Sep;130:1-8 PMID: 13811549
RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION.
Am J Med Sci. 1964 Dec;248:657-9 PMID: 14251902
The fate of antipyrine in man.
J Pharmacol Exp Ther. 1950 Jan;98(1):97-104 PMID: 15403625
Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis.
J Clin Invest. 1959 Sep;38:1498-508 PMID: 14412753
Metabolism of drugs in subjects with Laennec's cirrhosis.
Med Exp Int J Exp Med. 1959;1:290-2 PMID: 13804621

Article Info

Journal

Gut

Abbr.

Gut

ISSN

0017-5749

DOI

10.1136/gut.14.7.569

Published

1973-07-00

Pages

569-73

Language

English

Region

England

NLM ID

2985108R

PMCID

PMC1412804

Subset

External Links

PubMed source DOI: 10.1136/gut.14.7.569 PMC Full Text View journal details

Analysis Services

Determinants of serum antipyrine half-lives in patients with liver disease.

Contact

WeChat Official Account